C. Rubino

发表

Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team

Ronald N. Jones, S. Bhavnani, P. Ambrose, 2003, Antimicrobial Agents and Chemotherapy.

Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia

Thomas C. Baddeley, S. Gauthier, R. Staff, 2020, Journal of Alzheimer's disease : JAD.

Minimal Physiologically Based Pharmacokinetic and Drug‐Drug‐Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects

Mohamed Ismail, C. Rubino, V. H. Lee, 2018, Journal of clinical pharmacology.

Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia

S. Bhavnani, P. Ambrose, A. Forrest, 2009, Antimicrobial Agents and Chemotherapy.

Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia

Ronald N. Jones, R. Wunderink, J. Rello, 2017, Antimicrobial Agents and Chemotherapy.

Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection

D. Greenblatt, J. Harmatz, W. Nicholson, 2018, Journal of clinical pharmacology.

Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

K. Winthrop, S. Bhavnani, D. Griffith, 2021, European Journal of Drug Metabolism and Pharmacokinetics.

PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

S. Bhavnani, P. Ambrose, C. Bulik, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Time for Precision: A World Without Susceptibility Breakpoints

D. Andes, S. Bhavnani, P. Ambrose, 2018, Open forum infectious diseases.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model

D. Livermore, J. McCauley, S. Bhavnani, 2017, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution

S. Bhavnani, P. Ambrose, J. Hammel, 2020, Antimicrobial Agents and Chemotherapy.

Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults.

S. Bhavnani, P. Ambrose, A. Forrest, 2009, Pulmonary pharmacology & therapeutics.

Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia

Arthur J. L. Cooper, J. Korth-Bradley, S. Bhavnani, 2011, Antimicrobial Agents and Chemotherapy.

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.

B. Cirincione, J. Korth-Bradley, P. Ambrose, 2009, Diagnostic microbiology and infectious disease.

Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal Activity

S. Bhavnani, P. Ambrose, B. VanScoy, 2018, Antimicrobial Agents and Chemotherapy.

Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor

J. Sloan-Lancaster, S. V. Van Wart, C. Rubino, 2013, CPT: pharmacometrics & systems pharmacology.

Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue

J. Baldassarre, M. Dunne, S. V. Van Wart, 2015, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis

J. Chalmers, Jun Zou, H. Usansky, 2022, Clinical Pharmacokinetics.

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

S. Bhavnani, P. Ambrose, L. Friedrich, 2020, Antimicrobial Agents and Chemotherapy.

88 Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis (CF)

D. C. Griffith, G. Kearns, M. Dudley, 2011 .

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.

G. Drusano, S. Bhavnani, P. Ambrose, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against Itself

J. McCauley, S. Bhavnani, P. Ambrose, 2016, Antimicrobial Agents and Chemotherapy.

Determination of Appropriate Weight-Based Cutoffs for Empiric Cefazolin Dosing Using Data from a Phase 1 Pharmacokinetics and Safety Study of Cefazolin Administered for Surgical Prophylaxis in Pediatric Patients Aged 10 to 12 Years

J. Blumer, M. Schmitz, C. Rubino, 2015, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis

J. Chalmers, Jun Zou, H. Usansky, 2022, Clinical Pharmacokinetics.

Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis

Larry R. Smith, S. Sullivan, M. Mammen, 2017, Open Forum Infectious Diseases.

First-in-human investigation of the oral first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.

Suzanne F. Jones, A. Brenner, H. Burris, 2015 .

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints

D. C. Griffith, S. Cammarata, M. Dudley, 2022, Antimicrobial agents and chemotherapy.

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia

S. Gelone, S. Bhavnani, P. Ambrose, 2019, The Journal of antimicrobial chemotherapy.

Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory

R. Robson, M. Dudley, G. Moeck, 2016, Antimicrobial Agents and Chemotherapy.

Optimizing Therapy with Antibacterial Agents

J. Bradley, C. Rubino, 2007 .

Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired Pneumonia

Arthur J. L. Cooper, J. Korth-Bradley, S. Bhavnani, 2010, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Analysis for a Single 1,200-Milligram Dose of Oritavancin Using Data from Two Pivotal Phase 3 Clinical Trials

S. Bhavnani, P. Ambrose, G. Moeck, 2015, Antimicrobial Agents and Chemotherapy.

Frequentist and Bayesian Pharmacometric-Based Approaches To Facilitate Critically Needed New Antibiotic Development: Overcoming Lies, Damn Lies, and Statistics

Paul G. Ambrose, George L. Drusano, G. Drusano, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.

Alan Forrest, Arnold Louie, G. Drusano, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Adverse Drug Reactions and Drug-Drug Interactions

C. Rubino, W. Benton, Gretchen A. Irby, 2011 .

401A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor RPX7009 Alone, Meropenem Alone, and both in Combination (Carbavance) TID for 7 days in Healthy Adult Subjects

M. Dudley, J. Loutit, C. Rubino, 2014 .

Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12–17 Years of Age

J. Blumer, J. Bradley, J. Sullivan, 2015, The Pediatric infectious disease journal.

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

M. Dudley, S. Bhavnani, J. Loutit, 2018, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies

S. Bhavnani, P. Ambrose, Aryun Kim, 2019, Antimicrobial Agents and Chemotherapy.

Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations

G. Drusano, S. Bhavnani, P. Ambrose, 2015, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution

S. Bhavnani, P. Ambrose, E. Lakota, 2019, Antimicrobial Agents and Chemotherapy.

Ensuring quality pharmacokinetic analyses in antimicrobial drug development programs.

E. Lakota, C. Rubino, J. Bader, 2017, Current opinion in pharmacology.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects

M. Dudley, S. Bhavnani, J. Loutit, 2018, Antimicrobial Agents and Chemotherapy.

Meropenem-Vaborbactam Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses as Support for Dose Selection in Patients with Normal Renal Function and Varying Degrees of Renal Impairment

J. Loutit, M. Dudley, S. Bhavnani, 2017 .

Evaluation of Tigecycline Penetration into Colon Wall Tissue and Epithelial Lining Fluid Using a Population Pharmacokinetic Model and Monte Carlo Simulation

G. Drusano, J. Korth-Bradley, S. Bhavnani, 2007, Antimicrobial Agents and Chemotherapy.

A review of the pharmacokinetic and pharmacodynamic characteristics of beta-lactam/beta-lactamase inhibitor combination antibiotics in premature infants.

P. Gal, J. Ransom, C. Rubino, 1998, The Pediatric infectious disease journal.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with 1 Cefepime in an In Vitro Infection Model 2 3 Running title : PK-PD of Tazobactam

D. Livermore, J. McCauley, S. Bhavnani, 2017 .

A Multicenter Evaluation of Gentamicin Therapy in the Neonatal Intensive Care Unit

P. Gal, J. Ransom, C. L. Shaffer, 2001, Pharmacotherapy.

Erratum: Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore (Clinical Infectious Diseases (2007) 44, (79-86))

Alan Forrest, Paul G. Ambrose, George L. Drusano, 2007 .

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections

S. Flanagan, C. Rubino, 2021, Antimicrobial agents and chemotherapy.

Effect of a Clinical Pharmacist‐Managed Lipid Clinic on Achieving National Cholesterol Education Program Low‐Density Lipoprotein Goals

C. Rubino, J. Edmunds, M. Bozovich, 2000, Pharmacotherapy.

Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers

B. Gunn, L. Walker, E. Krauland, 2022, Science Translational Medicine.

Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods

S. Bhavnani, C. Rubino, W. Wicha, 2019, The Journal of antimicrobial chemotherapy.

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae

M. Huband, S. Bhavnani, P. Ambrose, 2023, Antimicrobial agents and chemotherapy.

Pharmacokinetic-Pharmacodynamic Analyses for Efficacy of Ceftaroline Fosamil in Patients with Community-Acquired Bacterial Pneumonia

T. Riccobene, S. Bhavnani, P. Ambrose, 2013, Antimicrobial Agents and Chemotherapy.

Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline

J. Korth-Bradley, S. Bhavnani, P. Ambrose, 2011, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data

S. Flanagan, E. Lakota, C. Rubino, 2018, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development.

B. Cirincione, D. Grasela, P. Ambrose, 2007, Diagnostic microbiology and infectious disease.

Population Pharmacokinetic Model for Gatifloxacin in Pediatric Patients

G. Kearns, R. Jacobs, B. Cirincione, 2007, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Model for Gatiﬂoxacin in Pediatric Patients (cid:1)

G. Kearns, R. Jacobs, B. Cirincione, 2007 .

Impact of Different Factors on the Probability of Clinical Response in Tigecycline-Treated Patients with Intra-Abdominal Infections

G. Drusano, J. Korth-Bradley, S. Bhavnani, 2009, Antimicrobial Agents and Chemotherapy.

Interference of Oritavancin on Coagulation Tests as Assessed In vitro and in a Phase 1 Study of Normal Healthy Volunteers

R. Robson, M. Dudley, G. Moeck, 2016 .

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters

Paul G. Ambrose, D. Andes, S. Bhavnani, 2017, Antimicrobial Agents and Chemotherapy.

Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers

C. Rubino, S. Farr, C. Y. Robinson, 2015, Clinical pharmacology : advances and applications.

Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.

G. Drusano, S. Bhavnani, P. Ambrose, 2008, Diagnostic microbiology and infectious disease.

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

M. Dudley, S. Bhavnani, J. Loutit, 2018, Antimicrobial Agents and Chemotherapy.

Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes

Lawrence Corey, Joshua T. Schiffer, Amalia Magaret, 2016, Science Translational Medicine.

A Phase 1 First‐in‐Human Single‐Ascending‐Dose Trial With ESB1609, a Selective Agonist to the Sphingosine‐1‐Phosphate Receptor 5

E. Liu, C. Barlow, S. Sankaranarayanan, 2023, Clinical pharmacology in drug development.

Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients

M. Schmitz, C. Rubino, W. Cetnarowski, 2020, Journal of clinical pharmacology.

Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease

S. Gauthier, R. Staff, B. Schelter, 2019, Journal of Alzheimer's disease : JAD.

591. Adintrevimab (ADI) Population Pharmacokinetics (PPK) in Phase 1 and Phase 2/3 COVID-19 Prevention and Treatment Study Participants

P. Ambrose, C. Rubino, Myra W. Popejoy, 2022, Open Forum Infectious Diseases.

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

S. Flanagan, S. Bhavnani, P. Ambrose, 2018, Antimicrobial Agents and Chemotherapy.

PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

S. Bhavnani, P. Ambrose, C. Bulik, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Evaluation of Exposure-Response Relationships Using Clinical Data: Basic Concepts and Applications

S. Bhavnani, P. Ambrose, C. Rubino, 2016 .

Delafloxacin Population Pharmacokinetics and Covariate Exploration

S. Bhavnani, P. Ambrose, A. Forrest, 2010 .

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

S. Flanagan, S. Bhavnani, E. Lakota, 2018 .

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients

A. Smits, T. Tomasik, P. Kwinta, 2021, The Pediatric infectious disease journal.

Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients

A. Smits, K. Hamed, K. Litherland, 2021, Antimicrobial Agents and Chemotherapy.

Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics.

J. Bradley, C. Rubino, 2007, Paediatric drugs.

GERD in Neonates and Pediatrics: Use of Omeprazole

P. Gal, J. Ransom, C. Rubino, 1999 .

effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers

C. Rubino, S. Farr, C. Y. Robinson, 2015 .

A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers

P. Belloni, Han Ting Ding, Jianshuang Wang, 2017, Advances in Therapy.

1727. Phase 1b Dose-ranging Study Demonstrates Tolerability and Pharmacokinetics (PK) of Oral Epetraborole at the Predicted Therapeutic Dosage for Mycobacterium avium Complex (MAC) Lung Disease

P. Eckburg, K. Krause, G. Talbot, 2022, Open Forum Infectious Diseases.

Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients

M. Dudley, S. Bhavnani, P. Ambrose, 2021, Antimicrobial agents and chemotherapy.

Pharmacokinetic-Pharmacodynamic Analysis for Efficacy of Ceftaroline Fosamil in Patients with Acute Bacterial Skin and Skin Structure Infections

G. Drusano, T. Riccobene, S. Bhavnani, 2014, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Evaluate In Vitro Susceptibility Test Interpretive Criteria for Ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

T. Riccobene, S. Bhavnani, P. Ambrose, 2013, Antimicrobial Agents and Chemotherapy.

Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community‐acquired bacterial pneumonia

T. Riccobene, S. Bhavnani, P. Ambrose, 2013, Journal of clinical pharmacology.

Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive

S. Bhavnani, P. Ambrose, C. Rubino, 2020, Antibiotics.

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies

S. Bhavnani, P. Ambrose, Aryun Kim, 2019, Antimicrobial Agents and Chemotherapy.

Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients

A. Smits, K. Hamed, K. Litherland, 2021, Antimicrobial agents and chemotherapy.

In vivo pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model.

P. Ambrose, A. Lepak, B. VanScoy, 2024, Antimicrobial agents and chemotherapy.

27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination

A. Brenner, H. Burris, J. Infante, 2015 .